Quote | Oric Pharmaceuticals Inc. (NASDAQ:ORIC)
Last: | $9.52 |
---|---|
Change Percent: | 0.43% |
Open: | $9.29 |
Close: | $9.52 |
High: | $9.69 |
Low: | $9.29 |
Volume: | 555,938 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
News | Oric Pharmaceuticals Inc. (NASDAQ:ORIC)
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treat...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces th...
Message Board Posts | Oric Pharmaceuticals Inc. (NASDAQ:ORIC)
Subject | By | Source | When |
---|---|---|---|
Price gaining last up | makinezmoney | investorshub | 06/20/2023 8:48:31 AM |
Price now | makinezmoney | investorshub | 05/30/2023 4:54:44 AM |
Price gaining | TheFinalCD | investorshub | 05/30/2023 12:36:19 AM |
$ORIC LOOKS LIKE $6 COMING | TheFinalCD | investorshub | 12/23/2022 7:14:12 PM |
$ORIC: Tapped $5.40....... still got steam | makinezmoney | investorshub | 12/23/2022 2:49:12 PM |
News, Short Squeeze, Breakout and More Instantly...
Oric Pharmaceuticals Inc. Company Name:
ORIC Stock Symbol:
NASDAQ Market:
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treat...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus competitor PRC2 inhibitors Preclinical synergy data in prostate cancer models reinforces th...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...